Audhya Paul K. 4

What Happened
Audhya Paul, Chief Medical Officer of KalVista Pharmaceuticals, was granted 100,000 restricted stock units (RSUs) on January 16, 2026. The grant is recorded as a derivative acquisition at $0.00 per unit (total reported value $0) — each RSU is a contingent right to receive one share of KalVista common stock upon settlement for no consideration.

Key Details

• Transaction date: 2026-01-16; Form 4 filed 2026-01-21 (5 days after the transaction). Form 4s are typically due within 2 business days, so this filing appears later than that standard.
• Grant: 100,000 RSUs; price recorded $0.00; total reported value $0 (derivative instrument).
• Vesting: 1/16th of the total RSUs vest on each quarterly anniversary of the vesting commencement date, beginning May 22, 2026 (i.e., quarterly vesting over 16 quarters/4 years), contingent on continued service.
• Shares owned after the transaction: not specified in the provided filing.
• No indication of tax withholding, 10b5-1 plan, or immediate sale of underlying shares in this filing.

Context
RSU grants are a form of equity compensation and do not represent an open-market purchase or sale. They convert into shares only as they vest (subject to the stated schedule and continued employment), so they are not an immediate signal of buying or selling in the market. Grants like this are common as part of executive compensation packages.